Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MNKD 
MannKind Corp (MNKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MNKD (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.71
1 Year Target Price $9.71
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.75% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio 40.82 | 1Y Target Price 9.71 |
Price to earnings Ratio 40.82 | 1Y Target Price 9.71 | ||
Volume (30-day avg) 7 | Beta 1.02 | 52 Weeks Range 3.38 - 7.63 | Updated Date 08/28/2025 |
52 Weeks Range 3.38 - 7.63 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.05 | Actual 0.05 |
Profitability
Profit Margin 10.87% | Operating Margin (TTM) 13.93% |
Management Effectiveness
Return on Assets (TTM) 10.63% | Return on Equity (TTM) - |
Valuation
Trailing PE 40.82 | Forward PE 29.94 | Enterprise Value 1245496224 | Price to Sales(TTM) 4.57 |
Enterprise Value 1245496224 | Price to Sales(TTM) 4.57 | ||
Enterprise Value to Revenue 4.13 | Enterprise Value to EBITDA 15.74 | Shares Outstanding 306828000 | Shares Floating 300980187 |
Shares Outstanding 306828000 | Shares Floating 300980187 | ||
Percent Insiders 1.66 | Percent Institutions 55.84 |
Upturn AI SWOT
MannKind Corp
Company Overview
History and Background
MannKind Corporation was founded in 1991 by Alfred Mann. Initially focused on various drug delivery technologies, the company has evolved to specialize in inhaled therapeutic products, primarily for endocrine and pulmonary diseases. Afrezza, its inhaled insulin product, has been a key focus.
Core Business Areas
- Therapeutics: Focuses on the development, manufacturing, and commercialization of pharmaceutical products for diseases such as diabetes and pulmonary arterial hypertension.
- Inhalation Technology: Develops and utilizes innovative inhalation technologies, particularly the Technosphere platform, for drug delivery.
Leadership and Structure
Michael Castagna is the Chief Executive Officer. The company has a standard corporate structure with a board of directors overseeing executive management.
Top Products and Market Share
Key Offerings
- Afrezza: Afrezza is an inhaled rapid-acting insulin used to control blood sugar in adults with diabetes mellitus. MannKind faces competition from traditional insulin injections and other rapid-acting insulin analogs such as NovoLog (NVO) and Humalog (LLY). Market share data fluctuates but is relatively small compared to established insulin products. Revenue numbers vary quarter to quarter, but Afrezza sales are a crucial indicator of MannKind's performance and growth potential. Recent estimated market share is in the single digits for rapid acting insulin.
- Tyvaso DPI: Partnered with United Therapeutics (UTHR) for Tyvaso DPI, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). MannKind is responsible for manufacturing. Revenue generated from this partnership is significant to MannKind's financial performance. United Therapeutics dominates the PAH treatment market, making them the key competitor in this space.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. The diabetes and pulmonary hypertension markets are substantial, with increasing demand for innovative drug delivery methods.
Positioning
MannKind is positioned as a specialty pharmaceutical company focusing on inhaled drug delivery. Its Technosphere technology provides a competitive advantage in certain therapeutic areas.
Total Addressable Market (TAM)
The global diabetes market is estimated to be in the hundreds of billions of dollars. The pulmonary hypertension market is smaller but still substantial. MannKind is positioned to capture a portion of these markets with its inhaled insulin and PAH treatments.
Upturn SWOT Analysis
Strengths
- Proprietary Technosphere technology
- Partnership with United Therapeutics for Tyvaso DPI
- Potential for rapid onset of action with inhaled products
- Experienced management team
Weaknesses
- Limited market share compared to established competitors
- Historical struggles with Afrezza adoption
- Reliance on partnerships for revenue
- History of financial losses
Opportunities
- Expansion of Afrezza market through increased awareness
- Development of new products using Technosphere technology
- Strategic partnerships for drug delivery
- Growing prevalence of diabetes and pulmonary hypertension
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for drug approvals
- Pricing pressures from insurance companies
- Potential for generic competition
Competitors and Market Share
Key Competitors
- LLY
- NVO
- UTHR
Competitive Landscape
MannKind's advantage lies in its Technosphere technology and inhaled delivery. Disadvantages include limited resources and market presence compared to larger pharmaceutical companies. Afrezza competes in a crowded insulin market; Tyvaso DPI leverages United Therapeutics' established market position.
Growth Trajectory and Initiatives
Historical Growth: Growth has been volatile, dependent on Afrezza sales and partnership revenue.
Future Projections: Analyst projections vary, but generally anticipate growth driven by Afrezza and Tyvaso DPI sales.
Recent Initiatives: Focus on expanding Afrezza sales force, securing formulary coverage, and pursuing new partnerships.
Summary
MannKind is a speculative pharmaceutical company with innovative inhaled drug delivery technology. Success depends on the market penetration of Afrezza and continued collaboration with United Therapeutics. While Tyvaso DPI revenue is promising, MannKind faces challenges in scaling Afrezza sales and competing with larger players. Financial stability and profitability remain key concerns and investors should watch for continued success in its sales and manufacturing collaborations
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Investor Presentations
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates may vary. Financial data is subject to change. Consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com | ||
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.